Structure of mycobacterial ATP synthase bound to the tuberculosis drug bedaquiline

Hui Guo,Gautier M. Courbon,Stephanie A. Bueler,Juntao Mai,Jun Liu,John L. Rubinstein

DOI: https://doi.org/10.1038/s41586-020-3004-3

IF: 64.8

2020-12-09

Nature

Abstract:Tuberculosis—the world's leading cause of death by infectious disease—is increasingly resistant to current first-line antibiotics^{<a href="/articles/s41586-020-3004-3#ref-CR1">1</a>}. The bacterium <i>Mycobacterium tuberculosis</i> (which causes tuberculosis) can survive low-energy conditions, allowing infections to remain dormant and decreasing their susceptibility to many antibiotics^{<a href="/articles/s41586-020-3004-3#ref-CR2">2</a>}. Bedaquiline was developed in 2005 from a lead compound identified in a phenotypic screen against <i>Mycobacterium smegmatis</i>^{<a href="/articles/s41586-020-3004-3#ref-CR3">3</a>}. This drug can sterilize even latent <i>M. tuberculosis</i> infections^{<a href="/articles/s41586-020-3004-3#ref-CR4">4</a>} and has become a cornerstone of treatment for multidrug-resistant and extensively drug-resistant tuberculosis^{<a href="/articles/s41586-020-3004-3#ref-CR1">1</a>,<a href="/articles/s41586-020-3004-3#ref-CR5">5</a>,<a href="/articles/s41586-020-3004-3#ref-CR6">6</a>}. Bedaquiline targets the mycobacterial ATP synthase^{<a href="/articles/s41586-020-3004-3#ref-CR3">3</a>}, which is an essential enzyme in the obligate aerobic <i>Mycobacterium</i> genus^{<a href="/articles/s41586-020-3004-3#ref-CR3">3</a>,<a href="/articles/s41586-020-3004-3#ref-CR7">7</a>}, but how it binds the intact enzyme is unknown. Here we determined cryo-electron microscopy structures of <i>M. smegmatis</i> ATP synthase alone and in complex with bedaquiline. The drug-free structure suggests that hook-like extensions from the α-subunits prevent the enzyme from running in reverse, inhibiting ATP hydrolysis and preserving energy in hypoxic conditions. Bedaquiline binding induces large conformational changes in the ATP synthase, creating tight binding pockets at the interface of subunits a and c that explain the potency of this drug as an antibiotic for tuberculosis.

multidisciplinary sciences

What problem does this paper attempt to address?

The paper attempts to address two main issues:

1. **Analyzing the structure of Mycobacterium tuberculosis ATP synthase and its binding mechanism with the drug Bedaquiline**:
- Tuberculosis is the leading cause of death from infectious diseases worldwide, and an increasing number of tuberculosis bacteria are developing resistance to existing first-line antibiotics.
- Bedaquiline is a drug targeting Mycobacterium tuberculosis ATP synthase, which can effectively treat multidrug-resistant and extensively drug-resistant tuberculosis.
- However, how Bedaquiline binds to the complete ATP synthase and its mechanism of action remains unclear.

2. **Revealing the self-inhibition mechanism of ATP synthase under low-energy conditions**:
- Mycobacterium tuberculosis can survive under low-energy conditions, allowing the infection to remain latent and reducing sensitivity to antibiotics.
- Research has found that ATP synthase prevents reverse operation under low-energy conditions through the extended structure of the α subunit, thereby inhibiting ATP hydrolysis and maintaining energy reserves.
- Understanding this self-inhibition mechanism helps in developing new anti-tuberculosis drugs.

Through these studies, the authors hope to provide a structural basis and theoretical support for the development of more effective anti-tuberculosis drugs.